• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Insulet Corp

NASDAQ:PODD

$18.00 -$0.65 (-3.49%)

REAL-TIME: Last trade at

Insulet Corporation to Present at Upcoming Investor Conferences

Canaccord Genuity Reiterates a 'Buy' on Insulet Corporation (PODD); Solid Q1; Gen2 Pod Still Awaiting FDA Clearance

Insulet breaks out above its 10-day MA, resistance is at $18.65 pivot

Insulet Corporation (PODD) Misses Posts Q1 Loss of $0.31

Insulet affirms Q2 revenue view $50M-$53M, consensus $51.49M

Insulet affirms FY12 revenue view $210M-$225M, consensus $215.26M

Insulet reports Q1 EPS (31c), consensus (28c)

Insulet Reports First Quarter 2012 Results

Pumping Its Way to Profits

Insulet Corporation to Present at the 11th Annual JMP Securities Research Conference

Insulet Corporation to Report First Quarter 2012 Financial Results on May 9, 2012

Rodman & Renshaw Upgrades Insulet Corporation (PODD) to Market Outperform

Avondale Partners Starts Insulet Corporation (PODD) at Market Outperform

Insulet initiated with an Outperform at Avondale

Insulet expands international distribution partnership with Ypsomed

Insulet Expands International Distribution Partnership With Ypsomed

Insulet management to meet with JPMorgan

Piper Jaffray Starts Insulet Corporation (PODD) at Neutral

Insulet initiated with a Neutral at Piper Jaffray

Insulet moves up in pre-market trade, resistance at $21.57

Canaccord Genuity Reiterates a 'Buy' on Insulet (PODD); Second Partner Creates Future Opportunity

Insulet announces global agreement with LifeScan

Insulet Announces Global Agreement With LifeScan, Inc to Integrate Their OneTouch Blood Glucose Monitoring Technologies Into the OmniPod(R) Insulin Pump

Insulet new OmniPod should be catalyst in FY12, says Barrington

Insulet Corporation to Present at the Leerink Swann Global Healthcare Conference

Insulet Corporation to Present at the Leerink Swann Global Healthcare Conference

Jefferies Maintains a 'Buy' on Insulet Corp (PODD)Waiting for the Next Gen Pod

Insulet Corporation (PODD) Misses Q4 EPS by 4c; Guides FY12 Revs

Insulet sees FY12 operating loss $25M-$35M

Insulet reports Q4 EPS (30c) vs. consensus (24c)

Insulet sees FY12 revenue $210M-$225M vs. consensus $218.36M

Insulet Reports Fourth Quarter and Full Year 2011 Results

Insulet Corporation to Report Fourth Quarter and Full Year 2011 Financial Results on February 9, 2012

Insulet Corporation to Report Fourth Quarter and Full Year 2011 Financial Results on February 9, 2012

Brean Murray Carret & Co. Starts Insulet Corporation (PODD) at Buy; Attractive Growth Story With Key Approval Near Term

Insulet initiated with a Buy at Brean Murray

Insulet weakness a buying opportunity, says JP Morgan

Global Health Care Outlook

Insulet Corp. (PODD) President and CEO Duane Desisto sells 20,000 Shares

Insulet Corporation to Present at the 30th Annual J.P. Morgan Healthcare Conference

See More Articles...